Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Development of cyclosporine A-loaded dry-emulsion formulation using highly purified glycerol monooleate for safe inhalation therapy.

Sato H, Ogawa K, Kojo Y, Kawabata Y, Mizumoto T, Yamada S, Onoue S.

Int J Pharm. 2013 May 1;448(1):282-9. doi: 10.1016/j.ijpharm.2013.03.026.

PMID:
23528280
2.

Inhalable dry-emulsion formulation of cyclosporine A with improved anti-inflammatory effects in experimental asthma/COPD-model rats.

Onoue S, Sato H, Ogawa K, Kojo Y, Aoki Y, Kawabata Y, Wada K, Mizumoto T, Yamada S.

Eur J Pharm Biopharm. 2012 Jan;80(1):54-60. doi: 10.1016/j.ejpb.2011.10.003.

PMID:
22008148
4.

Physicochemical stability study on cyclosporine A loaded dry-emulsion formulation with enhanced solubility.

Sato H, Ogawa K, Kojo Y, Suzuki H, Mizumoto T, Onoue S.

Chem Pharm Bull (Tokyo). 2015;63(1):54-8. doi: 10.1248/cpb.c14-00696.

5.

Formulation design and in vivo evaluation of dry powder inhalation system of new vasoactive intestinal peptide derivative ([R(15, 20, 21), L(17), A(24,25), des-N(28)]-VIP-GRR) in experimental asthma/COPD model rats.

Onoue S, Aoki Y, Matsui T, Kojo Y, Misaka S, Mizumoto T, Yamada S.

Int J Pharm. 2011 May 30;410(1-2):54-60. doi: 10.1016/j.ijpharm.2011.03.021.

PMID:
21419198
6.

In vitro and in vivo characterization on amorphous solid dispersion of cyclosporine A for inhalation therapy.

Onoue S, Sato H, Kawabata Y, Mizumoto T, Hashimoto N, Yamada S.

J Control Release. 2009 Aug 19;138(1):16-23. doi: 10.1016/j.jconrel.2009.04.014.

PMID:
19376169
7.

Inhalable powder formulation of a stabilized vasoactive intestinal peptide (VIP) derivative: anti-inflammatory effect in experimental asthmatic rats.

Misaka S, Aoki Y, Karaki S, Kuwahara A, Mizumoto T, Onoue S, Yamada S.

Peptides. 2010 Jan;31(1):72-8. doi: 10.1016/j.peptides.2009.09.032.

PMID:
19808073
8.

Development of inhalable nanocrystalline solid dispersion of tranilast for airway inflammatory diseases.

Onoue S, Aoki Y, Kawabata Y, Matsui T, Yamamoto K, Sato H, Yamauchi Y, Yamada S.

J Pharm Sci. 2011 Feb;100(2):622-33. doi: 10.1002/jps.22299.

PMID:
20653048
9.

Stable dry powder inhaler formulation of tranilast attenuated antigen-evoked airway inflammation in rats.

Kawabata Y, Aoki Y, Matsui T, Yamamoto K, Sato H, Onoue S, Yamada S.

Eur J Pharm Biopharm. 2011 Jan;77(1):178-81. doi: 10.1016/j.ejpb.2010.11.005.

PMID:
21081161
10.

Chemical synthesis and formulation design of a PEGylated vasoactive intestinal peptide derivative with improved metabolic stability.

Onoue S, Matsui T, Kato M, Mizumoto T, Liu B, Liu L, Karaki S, Kuwahara A, Yamada S.

Eur J Pharm Sci. 2013 Jun 14;49(3):382-9. doi: 10.1016/j.ejps.2013.04.009.

PMID:
23608612
11.

Novel dry powder formulation of ovalbumin for development of COPD-like animal model: Physicochemical characterization and biomarker profiling in rats.

Misaka S, Sato H, Yamauchi Y, Onoue S, Yamada S.

Eur J Pharm Sci. 2009 Jun 28;37(3-4):469-76. doi: 10.1016/j.ejps.2009.04.002.

PMID:
19491038
12.

Self-micellizing solid dispersion of cyclosporine A with improved dissolution and oral bioavailability.

Onoue S, Suzuki H, Kojo Y, Matsunaga S, Sato H, Mizumoto T, Yuminoki K, Hashimoto N, Yamada S.

Eur J Pharm Sci. 2014 Oct 1;62:16-22. doi: 10.1016/j.ejps.2014.05.006.

PMID:
24836392
13.

Inhalable sustained-release formulation of long-acting vasoactive intestinal peptide derivative alleviates acute airway inflammation.

Onoue S, Matsui T, Kuriyama K, Ogawa K, Kojo Y, Mizumoto T, Karaki S, Kuwahara A, Yamada S.

Peptides. 2012 Jun;35(2):182-9. doi: 10.1016/j.peptides.2012.03.021.

PMID:
22484228
14.

Cyclosporin nanosphere formulation for ophthalmic administration.

Khan W, Aldouby YH, Avramoff A, Domb AJ.

Int J Pharm. 2012 Nov 1;437(1-2):275-6. doi: 10.1016/j.ijpharm.2012.08.016.

PMID:
22951866
15.

Spray dried glyceryl monooleate-magnesium trisilicate dry powder as cubic phase precursor.

Shah MH, Biradar SV, Paradkar AR.

Int J Pharm. 2006 Oct 12;323(1-2):18-26.

PMID:
16846704
16.

Self-micellizing solid dispersion of cyclosporine A for pulmonary delivery: Physicochemical, pharmacokinetic and safety assessments.

Suzuki H, Ueno K, Mizumoto T, Seto Y, Sato H, Onoue S.

Eur J Pharm Sci. 2016 Sep 12;96:107-114. doi: 10.1016/j.ejps.2016.09.015. [Epub ahead of print]

PMID:
27634579
17.

Low-molecular-weight heparin (LMWH)-loaded large porous PEG-PLGA particles for the treatment of asthma.

Patel B, Gupta N, Ahsan F.

J Aerosol Med Pulm Drug Deliv. 2014 Feb;27(1):12-20. doi: 10.1089/jamp.2013.1073.

18.

Self-assembled micellar formulation of chafuroside A with improved anti-inflammatory effects in experimental asthma/COPD-model rats.

Onoue S, Matsui T, Aoki Y, Ishida H, Nukaya H, Kou K, Yamada S.

Eur J Pharm Sci. 2012 Jan 23;45(1-2):184-9. doi: 10.1016/j.ejps.2011.11.003.

PMID:
22108345
19.

Strategic application of self-micellizing solid dispersion technology to respirable powder formulation of tranilast for improved therapeutic potential.

Suzuki H, Kojo Y, Yakushiji K, Yuminoki K, Hashimoto N, Onoue S.

Int J Pharm. 2016 Feb 29;499(1-2):255-62. doi: 10.1016/j.ijpharm.2015.12.065.

PMID:
26748364
20.

Inhalable powder formulation of pirfenidone with reduced phototoxic risk for treatment of pulmonary fibrosis.

Onoue S, Seto Y, Kato M, Aoki Y, Kojo Y, Yamada S.

Pharm Res. 2013 Jun;30(6):1586-96. doi: 10.1007/s11095-013-0997-4.

PMID:
23430486
Items per page

Supplemental Content

Support Center